Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"LongeVC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LongeVC Joins Freedom Biosciences\u2019 Funding Round for Psychedelic-Powered Mental Health Care","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Freedom Biosciences

    Menu

    Freedom Biosciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Freedom Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LongeVC Joins Freedom Biosciences’ Funding Round for Psychedelic-Powered Mental Health Care

              Details:

              The net proceeds will be used by the company to focus on its FREE001, a ketamine treatment that’s been demonstrated in clinical trials to have more durable effects than ketamine.

              Lead Product(s): Ketamine Hydrochloride

              Therapeutic Area: Psychiatry/Psychology Product Name: FREE001

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: LongeVC

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing February 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Freedom Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments

              Details:

              The new financing will help the company advance its current lead ketamine program as well as further multiple additional exploratory programs. Program FREE001 is a ketamine treatment that’s been demonstrated in clinical trials to have more durable effects than ketamine.

              Lead Product(s): Ketamine Hydrochloride

              Therapeutic Area: Psychiatry/Psychology Product Name: FREE001

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: MBX Capital

              Deal Size: $10.5 million Upfront Cash: Undisclosed

              Deal Type: Financing August 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Freedom Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments

              Details:

              The company will use the net proceeds to focus on its FREE001, a ketamine treatment that’s been demonstrated in clinical trials to have more durable effects than ketamine.

              Lead Product(s): Ketamine Hydrochloride

              Therapeutic Area: Psychiatry/Psychology Product Name: FREE001

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: MBX Capital

              Deal Size: $10.5 million Upfront Cash: Undisclosed

              Deal Type: Financing August 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY